Background It is known that coronavirus disease-2019 (COVID-19) pneumonia causes
cytokine storm, and treatment modalities are being developed on inhibition of …

Purpose This cross-sectional observational study aims to report preliminary data from the
first experience using tocilizumab for patients with severe acute respiratory syndrome …

Background This study sought to evaluate and compare the effectiveness of
plasmapheresis, Tocilizumab, and Tocilizumab with plasmapheresis treatment on the …

Background: India recently encountered fierce second wave of coronavirus disease (COVID-
19), and scarcity of novel medications added to the management challenges. Various …

Nosocomial infections pose an imminent challenge to hospitalized Coronavirus disease-19
(COVID-19) patients due to complex interplay of dysregulated immune response combined …

Purpose Hyperinflammation in severe COVID-19 infection increases the risk of respiratory
failure and one of the cogent reasons of mortality associated with COVID-19. Baricitinib, a …

The coronavirus disease 2019 (COVID-19) has caused a global pandemic, resulting in
considerable morbidity and mortality. Tocilizumab, an inhibitor of IL-6, has been widely …

OBJECTIVES: Since the onset of the coronavirus disease 2019 pandemic, immune
modulators have been considered front-line candidates for the management of patients …

Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), has a wide clinical spectrum with variable severity [1–3] …

Objective To summarise the available information on efficacy and safety of
immunomodulatory agents in SARS-CoV-2 infection. Methods As part of a European …